Objective: To compare the survival in hospital admitted Corona patients receiving standard therapy alone and those receiving Remdesivir with standard treatment within 14 days after admission, using Kaplan Meier analysis and Cox regression analysis.

 Methods: It was a quasi-experimental study conducted in the Institute of Molecular Biology and Biotechnology (IMBB) department at the University of Lahore. 80 COVID-19 patients of both genders were included in this study. Out of which, 40 COVID-19 patients were given standard treatment plus Remdesivir, while the remaining 40 COVID-19 patients were given standard treatment alone. Patients were followed up for 14 days during which time their survival was noted. The Kaplan-Meier-         technique is used for survival analysis, Cox regression analysis was conducted to assess the relative contribution of risk factors of mortality in COVID-19 patients.

Results: The two groups were gender-matched with 82.4% males and 17.6% females in the treatment group whereas there were 83.3% males and 16.7% females in a control group respectively. Mean ages were 45.12±16.93 years, whereas, in the control group, mean ages were 60.69 years with a standard deviation of 11.13 years. The median survival in the treatment group was 9.00 days control group as well as in cases. The survival between the two groups was not statistically significantly different between the two groups (p=0.69). Survival was analyzed against treatment after adjusting for age, IL-6 levels, and gender. It was found that except age (odd ratio=0.96, p value=0.05) neither treatment type (odd ratio=1.39, p value=0.50), serum level of IL-6 (Odd ratio=0.85, p value=0.11) nor gender (Odd ratio=0.90, p value=0.86) affected survival of patients.

Keywords: Remdesivir, Kaplan-Meier approach, cox regression analysis.